CN116712423A - 治疗特定患者群体的神经变性病症的方法 - Google Patents
治疗特定患者群体的神经变性病症的方法 Download PDFInfo
- Publication number
- CN116712423A CN116712423A CN202310582394.5A CN202310582394A CN116712423A CN 116712423 A CN116712423 A CN 116712423A CN 202310582394 A CN202310582394 A CN 202310582394A CN 116712423 A CN116712423 A CN 116712423A
- Authority
- CN
- China
- Prior art keywords
- subject
- apoe4
- disease
- mild
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216404P | 2015-09-10 | 2015-09-10 | |
| US62/216,404 | 2015-09-10 | ||
| US201662290287P | 2016-02-02 | 2016-02-02 | |
| US62/290,287 | 2016-02-02 | ||
| US201662302027P | 2016-03-01 | 2016-03-01 | |
| US62/302,027 | 2016-03-01 | ||
| US201662365809P | 2016-07-22 | 2016-07-22 | |
| US62/365,809 | 2016-07-22 | ||
| CN201680052760.4A CN108289870A (zh) | 2015-09-10 | 2016-09-09 | 治疗特定患者群体的神经变性病症的方法 |
| PCT/US2016/051091 WO2017044840A1 (en) | 2015-09-10 | 2016-09-09 | Methods of treating neurodegenerative disorders in a particular patient population |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680052760.4A Division CN108289870A (zh) | 2015-09-10 | 2016-09-09 | 治疗特定患者群体的神经变性病症的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116712423A true CN116712423A (zh) | 2023-09-08 |
Family
ID=58240195
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310582394.5A Pending CN116712423A (zh) | 2015-09-10 | 2016-09-09 | 治疗特定患者群体的神经变性病症的方法 |
| CN201680052760.4A Pending CN108289870A (zh) | 2015-09-10 | 2016-09-09 | 治疗特定患者群体的神经变性病症的方法 |
| CN202310582365.9A Pending CN116712422A (zh) | 2015-09-10 | 2016-09-09 | 治疗特定患者群体的神经变性病症的方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680052760.4A Pending CN108289870A (zh) | 2015-09-10 | 2016-09-09 | 治疗特定患者群体的神经变性病症的方法 |
| CN202310582365.9A Pending CN116712422A (zh) | 2015-09-10 | 2016-09-09 | 治疗特定患者群体的神经变性病症的方法 |
Country Status (21)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2960625T3 (es) | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| EP3347002B1 (en) * | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| CN114805211B (zh) | 2017-03-21 | 2024-08-23 | 润佳(苏州)医药科技有限公司 | 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳(苏州)医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| MX2021001287A (es) * | 2018-08-01 | 2021-07-15 | Alzheon Inc | Métodos para tratar trastornos neurodegenerativos. |
| SI4296670T1 (sl) * | 2018-08-01 | 2026-04-30 | Alzheon, Inc. | Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳(苏州)医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| PH12021553196A1 (en) * | 2019-06-17 | 2022-11-07 | Alzheon Inc | Methods for treating neurodegenerative disorders |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳(苏州)医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| AU2022405026A1 (en) * | 2021-12-09 | 2024-06-20 | Alzheon, Inc. | Alz-801 for use in treating alzheimer's disease |
| WO2023150381A1 (en) * | 2022-02-07 | 2023-08-10 | Alzheon, Inc. | Alz-801 for use in treating a covid-19 associated neurological symptom |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101600730A (zh) * | 2006-10-12 | 2009-12-09 | 贝鲁斯健康(国际)有限公司 | 递送3-氨基-1-丙磺酸的方法、化合物、组合物和载体 |
| CN102834095A (zh) * | 2009-11-03 | 2012-12-19 | 法奈科斯公司 | 治疗阿尔茨海默病的新疗法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| CA2142300C (en) | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| EP1664601B1 (en) | 2003-08-11 | 2016-10-12 | California Institute Of Technology | Microfluidic large scale integration |
| US20060251714A1 (en) * | 2005-04-12 | 2006-11-09 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| SG173409A1 (en) | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20120009125A1 (en) | 2010-07-06 | 2012-01-12 | Lombard Jay L | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| MX353096B (es) | 2010-08-19 | 2017-12-19 | Buck Institute For Age Res Star | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
| US20150118231A1 (en) * | 2012-05-08 | 2015-04-30 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| HUE044737T2 (hu) * | 2013-05-06 | 2019-11-28 | Baxalta Inc | Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel |
| NZ723884A (en) | 2014-02-08 | 2023-02-24 | Genentech Inc | Methods of treating alzheimer’s disease |
| ES2960625T3 (es) * | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| EP3347002B1 (en) * | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
-
2016
- 2016-09-09 EP EP16845181.3A patent/EP3347002B1/en active Active
- 2016-09-09 PL PL16845181.3T patent/PL3347002T3/pl unknown
- 2016-09-09 SM SM20230250T patent/SMT202300250T1/it unknown
- 2016-09-09 ES ES16845181T patent/ES2952727T3/es active Active
- 2016-09-09 RS RS20260811A patent/RS68293B1/en unknown
- 2016-09-09 MD MDE20180700T patent/MD3347002T2/ro unknown
- 2016-09-09 WO PCT/US2016/051091 patent/WO2017044840A1/en not_active Ceased
- 2016-09-09 DK DK16845181.3T patent/DK3347002T3/da active
- 2016-09-09 SI SI201631729T patent/SI3347002T1/sl unknown
- 2016-09-09 KR KR1020187009381A patent/KR102412997B1/ko active Active
- 2016-09-09 US US15/758,405 patent/US11191742B2/en active Active
- 2016-09-09 JP JP2018512564A patent/JP6789579B2/ja active Active
- 2016-09-09 HU HUE16845181A patent/HUE062511T2/hu unknown
- 2016-09-09 LT LTEPPCT/US2016/051091T patent/LT3347002T/lt unknown
- 2016-09-09 AU AU2016319107A patent/AU2016319107B2/en active Active
- 2016-09-09 CN CN202310582394.5A patent/CN116712423A/zh active Pending
- 2016-09-09 HR HRP20230809TT patent/HRP20230809T1/hr unknown
- 2016-09-09 RS RS20230603A patent/RS64481B1/sr unknown
- 2016-09-09 EP EP23176559.5A patent/EP4275750B1/en active Active
- 2016-09-09 MX MX2018003023A patent/MX392677B/es unknown
- 2016-09-09 FI FIEP16845181.3T patent/FI3347002T3/fi active
- 2016-09-09 KR KR1020227009418A patent/KR102547164B1/ko active Active
- 2016-09-09 CN CN201680052760.4A patent/CN108289870A/zh active Pending
- 2016-09-09 PT PT168451813T patent/PT3347002T/pt unknown
- 2016-09-09 CN CN202310582365.9A patent/CN116712422A/zh active Pending
- 2016-09-09 CA CA2997376A patent/CA2997376C/en active Active
- 2016-09-09 SM SM20260257T patent/SMT202600257T1/it unknown
-
2018
- 2018-03-09 MX MX2022003128A patent/MX2022003128A/es unknown
-
2020
- 2020-09-28 JP JP2020161995A patent/JP7128536B2/ja active Active
-
2021
- 2021-09-17 US US17/477,886 patent/US20220096406A1/en not_active Abandoned
-
2022
- 2022-08-12 JP JP2022128786A patent/JP2022145949A/ja active Pending
-
2023
- 2023-09-06 US US18/462,238 patent/US20230414541A1/en active Pending
-
2025
- 2025-02-17 JP JP2025023627A patent/JP2025065545A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101600730A (zh) * | 2006-10-12 | 2009-12-09 | 贝鲁斯健康(国际)有限公司 | 递送3-氨基-1-丙磺酸的方法、化合物、组合物和载体 |
| CN102834095A (zh) * | 2009-11-03 | 2012-12-19 | 法奈科斯公司 | 治疗阿尔茨海默病的新疗法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7128536B2 (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| KR101918669B1 (ko) | 신경 장애 치료용 신규 조성물 | |
| US11116773B2 (en) | Method of treating dementia | |
| US12138269B2 (en) | Method of treating dementia | |
| CN113939276A (zh) | 用于治疗精神障碍、行为障碍、认知障碍的药物组合物和方法 | |
| WO2020222799A1 (en) | A method of treating mental, behavioral, cognitive disorders | |
| US20100035927A1 (en) | Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia | |
| US20180250249A1 (en) | Methods of treating neurodegenerative disorders in a particular population | |
| HK40094581A (en) | Treatment of alzheimer's disease in a particular patient population | |
| HK1257874B (en) | Treatment of alzheimer's disease in a particular patient population |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Massachusetts Applicant after: ALZHEON, Inc. Address before: Massachusetts Applicant before: ALZHEON, Inc. |